SCHEMBL20914008

SCHEMBL20914008

COc1cccc2oc(-c3c(C(=O)NCCO)[nH]c4c(-c5ccccc5)c(C(F)(F)F)nn4c3=O)nc12

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 2/20 0.33
▸ PDCD1 Q15116 1/20 0.33
▸ CD274 Q9NZQ7 1/20 0.33
▸ F2RL3 Q96RI0 2/20 0.33
▸ ADORA2A P29274 2/20 0.33
▸ MAOB P27338 1/20 0.33
▸ HTR3A P46098 2/20 0.32
▸ KCNH2 Q12809 2/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ TOP2A P11388 1/20 0.32
▸ FYN P06241 1/20 0.32
▸ KCNA5 P22460 1/20 0.32
▸ TNKS O95271 1/20 0.31
▸ TNKS2 Q9H2K2 1/20 0.31
▸ PARP2 Q9UGN5 1/20 0.31
▸ PDE4B Q07343 1/20 0.31
▸ ARF6 P62330 1/20 0.31
▸ PDE2A O00408 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20818972 0.94 NPC1 (0.35) TAAR1F2RL3ADORA2AHTR3AKCNH2
SCHEMBL20837252 0.92 FYN (0.36) TAAR1F2RL3FYN
SCHEMBL20914000 0.92 F2RL3 (0.33) F2RL3ADORA2AMAOBHTR3AKCNH2
SCHEMBL20837044 0.91 F2RL3 (0.33) F2RL3ADORA2AMAOBHTR3AKCNH2
SCHEMBL20914027 0.90 PTGER1 (0.36) F2RL3ADORA2AMAOBHTR3AKCNH2
SCHEMBL20819040 0.89 TNKS (0.35) F2RL3ADORA2AMAOBTOP2ATNKS
SCHEMBL20913950 0.89 PDE4B (0.35) F2RL3ADORA2AHTR3AKCNH2CYP3A4
SCHEMBL20913948 0.89 PDE4B (0.35) F2RL3ADORA2AHTR3AKCNH2CYP3A4
SCHEMBL20914053 0.88 PDE4B (0.34) F2RL3HTR3AKCNH2CYP3A4TOP2A
SCHEMBL20913994 0.88 POLB (0.37) F2RL3ADORA2AMAOBTOP2ATNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 TAAR1 3134/4885PDCD1 389/4885CD274 1635/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 TAAR1 3134/4885PDCD1 389/4885CD274 1635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback